Intellia therapeutics revenue
Nettet3. nov. 2024 · INTELLIA THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Amounts in thousands, except per share data) Three … Nettet6. apr. 2024 · Intellia Therapeutics (NASDAQ:NTLA) has a recorded annual revenue of $52.12 million. How much profit does Intellia Therapeutics generate each year? Intellia Therapeutics (NASDAQ:NTLA) has a recorded net income of -$474.19 million. NTLA has generated -$6.18 earnings per share over the last four quarters.
Intellia therapeutics revenue
Did you know?
NettetIntellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. Our company’s unique strengths … Nettet5. mai 2024 · Intellia Therapeutics, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $11.25 million for the quarter ended March …
Nettet14. apr. 2024 · Intellia Therapeutics shares last traded at $35.16, with a volume of 86,959 shares changing hands. ... The business’s revenue was up 5.4% compared to the … Nettet28. jul. 2024 · As of Q121, Intellia reported a cash position of $995m, down from $1.1bn in Q121. The company earned $11.3m of collaboration revenues in Q121, and made a net loss of $147m. Net loss in FY21 was...
NettetIntellia Therapeutic’s stock (NASDAQ: NTLA), a biotechnology company developing treatments using the CRISPR gene-editing system, has seen a fall of 31% in a month, … Nettet15. mar. 2024 · The collaboration revenue of Intellia therapeutics in 2024 was 33 million U.S. dollars. Intellia Therapeutics is a U.S.-based biotech company focusing on the …
Nettet12 timer siden · Two stocks that analysts appear to be bullish on right now are Intellia Therapeutics (NTLA-2.79%) and Rivian Automotive ... Last year, Rivian reported $1.7 billion in revenue, ...
NettetTotal Enterprise Value to Total Revenue (ttm) 39.02. ... John Leonard built Intellia Therapeutics with Jennifer Doudna, the Nobel Prize-winning scientist who pioneered gene editing technology. praying for death enemiesNettet13. apr. 2024 · The firm had revenue of $13.60 million during the quarter, compared to the consensus estimate of $10.71 million. Intellia Therapeutics had a negative return on equity of 48.70% and a negative net margin of 909.78%. The firm's revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business … scon-cb-100wai-rc-0-2Nettet13. apr. 2024 · The firm had revenue of $13.60 million during the quarter, compared to the consensus estimate of $10.71 million. Intellia Therapeutics had a negative return on … scon-cal-60waiNettet23. feb. 2024 · Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 0% and 11.06%, respectively, for the quarter ended December 2024. scon-cb-400wai-cc-0-2-spNettet24. feb. 2024 · Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress - On track to present additional ... March 7, 2024. Intellia ... Collaboration Revenue: Collaboration revenue increased by $6.3 million to $12.9 million during the fourth quarter of 2024, ... praying for comfort and healingNettetIntellia Therapeutics, Inc. Healthcare Biotechnology USA statements Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. s-con bryan texasNettet13. mar. 2024 · Intellia Therapeutics's revenue was up 5.4% on a year-over-year basis. On average, equities research analysts expect that Intellia Therapeutics, Inc. will post -5.79 earnings per share for the current fiscal year. Insiders Place Their Bets. 3 Genomics Stocks to Buy Now; In other Intellia Therapeutics news, CFO Glenn Goddard the SEC … praying for dead souls in christianity